Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia

This publication has 21 references indexed in Scilit:

• Circulating Angiogenic Factors and the Risk of Preeclampsia
  New England Journal of Medicine, 2004
• Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal–fetal interface in the mouse placenta
  Proceedings of the National Academy of Sciences, 2003
• Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria
  Journal of Biological Chemistry, 2003
• Recent Insights into the Pathogenesis of Pre-eclampsia
  Placenta, 2002
• Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome
  The American Journal of Pathology, 2002
• Birthweight by gestational age in Norway
  Acta Obstetricia et Gynecologica Scandinavica, 2000
• Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
  Published by Wolters Kluwer Health ,2000
• Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre‐eclampsia
  BJOG: An International Journal of Obstetrics and Gynaecology, 1999
• Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre‐eclampsia
  BJOG: An International Journal of Obstetrics and Gynaecology, 1997
• Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre‐eclampsia
  European Journal of Clinical Investigation, 1996